 Bone Density Conservation Agents
"Bone Density Conservation Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
| Descriptor ID |
D050071
|
| MeSH Number(s) |
D27.505.696.242
|
| Concept/Terms |
Antiresorptive Agents- Antiresorptive Agents
- Bone Resorption Inhibitors
- Inhibitors, Bone Resorption
- Resorption Inhibitors, Bone
- Bone Resorption Inhibitory Agents
- Antiresorptive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Bone Density Conservation Agents".
Below are MeSH descriptors whose meaning is more specific than "Bone Density Conservation Agents".
This graph shows the total number of publications written about "Bone Density Conservation Agents" by people in UAMS Profiles by year, and whether "Bone Density Conservation Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2023 | 3 | 0 | 3 | | 2022 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 | | 2017 | 1 | 1 | 2 | | 2015 | 2 | 1 | 3 | | 2014 | 6 | 0 | 6 | | 2013 | 6 | 2 | 8 | | 2012 | 5 | 3 | 8 | | 2011 | 4 | 1 | 5 | | 2010 | 2 | 1 | 3 | | 2009 | 1 | 1 | 2 | | 2008 | 1 | 0 | 1 | | 2007 | 4 | 0 | 4 | | 2006 | 2 | 1 | 3 | | 2005 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Bone Density Conservation Agents" by people in Profiles over the past ten years.
-
Bellido T. Bisphosphonates for osteoporosis: from bench to clinic. J Clin Invest. 2024 Mar 15; 134(6).
-
Nicholson G, Carlson KB, Hernandez RK, Schenfeld J, Cadieux B, Henry D, De Sousa Barbosa VJ, Saad H. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018. Am J Clin Oncol. 2024 Apr 01; 47(4):177-184.
-
Bittrich M, Hetterich R, Solimando AG, Krebs M, Loda S, Danhof S, Anton S, Zhou X, Kerscher A, Beilhack A, Kort?m KM, Rasche L, Einsele H, Knop S, Hartmann S. Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence. Clin Exp Med. 2023 Dec; 23(8):5215-5226.
-
Keisner SV. Prevention of Skeletal-Related Events With Extended-Interval Denosumab: A Review of the Literature. Ann Pharmacother. 2024 Feb; 58(2):174-184.
-
Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D'Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol. 2022 03 01; 40(7):787-800.
-
Sabol HM, Ferrari AJ, Adhikari M, Amorim T, McAndrews K, Anderson J, Vigolo M, Lehal R, Cregor M, Khan S, Cuevas PL, Helms JA, Kurihara N, Srinivasan V, Ebetino FH, Boeckman RK, Roodman GD, Bellido T, Delgado-Calle J. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer Res. 2021 10 01; 81(19):5102-5114.
-
Gurram PR, Castillo NE, Esquer Garrigos Z, Vijayvargiya P, Abu Saleh OM. A Dimorphic Diagnosis of a Pleomorphic Disease: An Unusual Cause of Hypercalcemia. Am J Med. 2020 11; 133(11):e659-e662.
-
Lau LH, Cliff ERS, Wong V, Wong H, Torkamani N, Eer A, Weickhardt A, Grossmann M. Hypocalcaemia following denosumab in prostate cancer: A clinical review. Clin Endocrinol (Oxf). 2020 06; 92(6):495-502.
-
Montgomery C, Couch C, Emory CL, Nicholas R. Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. J Knee Surg. 2019 Apr; 32(4):331-336.
-
Murphy PZ, Iranikhah M, Deas CM, Freeman MK. Fracture Risk Following Discontinuation of Teriparatide: A Review of the Literature. Consult Pharm. 2018 Jul 01; 33(7):365-375.
-
Jain N, Reilly RF. Hungry bone syndrome. Curr Opin Nephrol Hypertens. 2017 07; 26(4):250-255.
-
Deng L, Peng Y, Jiang Y, Wu Y, Ding Y, Wang Y, Xu D, Fu Q. Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles. Int J Mol Sci. 2017 May 08; 18(5).
-
Kennel KA, Maraka S. Authors' reply to Minisola and colleagues, Kausar, and Sharvill. BMJ. 2015 Nov 04; 351:h5873.
-
Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ. 2015 Sep 02; 351:h3783.
-
Plotkin LI, Gortazar AR, Davis HM, Condon KW, Gabilondo H, Maycas M, Allen MR, Bellido T. Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor ?B ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading. J Biol Chem. 2015 Jul 31; 290(31):18934-42.
-
Suva LJ, Makhoul I. Bone: Will breast cancer chemoprevention stand on 'solid bone'? Nat Rev Endocrinol. 2015 Mar; 11(3):138-9.
-
Hill Gallant KM, Gallant MA, Brown DM, Sato AY, Williams JN, Burr DB. Raloxifene prevents skeletal fragility in adult female Zucker Diabetic Sprague-Dawley rats. PLoS One. 2014; 9(9):e108262.
-
Hinson AM, Siegel ER, Stack BC. Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis. J Oral Maxillofac Surg. 2015 Jan; 73(1):53-62.
-
Pawlowski JW, Martin BR, McCabe GP, Ferruzzi MG, Weaver CM. Plum and soy aglycon extracts superior at increasing bone calcium retention in ovariectomized Sprague Dawley rats. J Agric Food Chem. 2014 Jul 02; 62(26):6108-17.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|